Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis

被引：0
|
作者：
Korn, Jonathan [1 ]
Medin, Jennie [2 ]
Fang, Juanzhi [3 ]
Putzki, Norman [2 ]
机构：
[1] QuintilesIMS, Burlington, MA USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Novartis Pharmaceut, E Hanover, NJ USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.397
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Persistence and adherence of fingolimod compared with other disease modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis
    Bergvall, N.
    Lahoz, R.
    Agashivala, N.
    Pradhan, A.
    Capkun-Niggli, G.
    Korn, J. R.
    Petrilla, A. A.
    Karkare, S. U.
    McGuiness, C. Balderston
    Makin, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 520 - 521
  • [2] PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES
    Galaznik, A.
    Rusli, E.
    Lempernesse, B.
    Shilnikova, A.
    Ransom, J.
    Berger, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S287 - S287
  • [3] Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data
    Engmann, Natalie J.
    Sheinson, Danny
    Bawa, Komal
    Ng, Carmen D.
    Pardo, Gabriel
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (05): : 639 - 649
  • [4] Persistence and Adherence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis in US Commercial Claims Databases
    Engmann, N.
    Yang, E.
    Fiore, D.
    Pardo, G.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 46 - 46
  • [5] Injectable disease-modifying therapies cycling versus switching to fingolimod: a retrospective US claims study of risk of MS related relapses
    da Silva, Maria Cecilia Vieira
    Li, Yunfeng
    Meng, Xiangyi
    Zhou, Huanxue
    Piao, Olivia Wenxian
    Kutz, Christen
    Conway, Devon
    [J]. NEUROLOGY, 2018, 90
  • [6] Adherence and Persistence to Disease-Modifying Therapies for Multiple Sclerosis and Their Impact on Clinical and Economic Outcomes in a US Claims Database
    Pineda, Elmor
    Ng, Carmen
    Sheinson, Daniel
    Bonine, Nicole
    Pardo, Gabriel
    [J]. NEUROLOGY, 2021, 96 (15)
  • [7] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    [J]. Journal of Neurology, 2017, 264 : 2325 - 2329
  • [8] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Lattanzi, Simona
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carlini, Giulia
    Pulcini, Alessandra
    Provinciali, Leandro
    Silvestrini, Mauro
    [J]. JOURNAL OF NEUROLOGY, 2017, 264 (11) : 2325 - 2329
  • [9] Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
    Pardo, Gabriel
    Pineda, Elmor D.
    Ng, Carmen D.
    Bawa, Komal K.
    Sheinson, Daniel
    Bonine, Nicole G.
    [J]. NEUROLOGY AND THERAPY, 2022, 11 (01) : 337 - 351
  • [10] Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
    Gabriel Pardo
    Elmor D. Pineda
    Carmen D. Ng
    Komal K. Bawa
    Daniel Sheinson
    Nicole G. Bonine
    [J]. Neurology and Therapy, 2022, 11 : 337 - 351
12345